MPP signs first COVID-19 licensing deal over MSD’s molnupiravir

28-10-2021

Alex Baldwin

MPP signs first COVID-19 licensing deal over MSD’s molnupiravir

Atmosphere1 / Shutterstock.com

UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).


MPP, LMIC, MSD, Merck, Emory University, Ridkgeback Biotherapteutics

LSIPR